DailyIQ
Last updated1 minute ago

CLX·The Clorox Company

$83.02
-0.50 (-0.60%)
High
$84.40
Open
$83.59
Market Cap
9.83B
52W High
$128.90
Low
$82.72
P. Close
$83.02
P/E
16.75
52W Low
$79.12
Fwd P/E
13.38
DailyIQ Est.
$90.42
Inst. Ownership
2.9%
Short Interest
7.17%
Days to Cover
2.9
Technical Score (1D)
18
BEARISH
News Sentiment
64
BULLISH
On Oct 7, a market‑analysis piece described The Clorox Company (CLX) as a dividend stock with a 6 % or higher yield after recent selloffs, noting that long‑term yields above 5 % create a favorable environment for income investors. The article highlighted potential valuation upside for CLX while acknowledging inflationary headwinds and payout risks, concluding that the upside potential outweighed the risks. On Oct 6, a separate report detailed CLX’s launch of the Clorox Purell ProCare™ health platform, which merges its CloroxPro division with the recently acquired GOJO brand, providing professional and healthcare customers unified access to Clorox, Purell, Pine‑Sol, and Glad through a single sales and distribution network. The same day, another analysis compared CLX with Colgate‑Palmolive, noting that CLX is actively rebuilding market share and strengthening its brands, expanding its health and hygiene platform through the GOJO acquisition, and leveraging innovation, pricing, and digital capabilities to navigate a volatile consumer‑staples environment. Together, these reports portray CLX as pursuing both dividend attractiveness and strategic growth in the health and hygiene sector.
LOW TARGET
$77 -7.3%
6 analysts
MEAN TARGET
$100 +20.5%
20 analysts
HIGH TARGET
$154 +85.5%
2 analysts
PRICE RANGE
$77.00 - $154.00
SB / B / H / S / SS
1/1/17/8/1
DAILYIQ EST.
$90.42 (+8.9%)
Sector
Consumer Defensive
Industry
Household & Personal Products
Exchange
NYQ
Country
United States
Symbol
CLX
Description
The Clorox Company is a global consumer staples manufacturer, primarily focused on household and healthcare essentials. Its diverse product portfolio spans four key segments: Health and Wellness, Household, Lifestyle, and International. Clorox's value proposition centers on providing trusted brands like Clorox, Glad, and Brita, offering consumers solutions for cleaning, home care, and personal wellness needs. The company distributes its products through a broad network of retailers, including mass merchants, grocery stores, and online channels, ensuring widespread accessibility. With a history dating back to 1913, Clorox has established a strong competitive position by consistently delivering essential products that meet everyday consumer demands.
Bought (1Y)
0 shares
$0
Sold (1Y)
1,958 shares
$187K
Breber Pierre R-
Award/Grant416.615 shares2026-09-30
Plaines Stephanie-
Award/Grant339.464 shares2026-09-30
Shattock Matthew J-
Award/Grant648.068 shares2026-09-30
WEINER RUSSELL J-
Award/Grant416.615 shares2026-09-30
WILLIAMS CHRISTOPHER J-
Award/Grant339.464 shares2026-09-30
65/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
45.2%
Net Margin
11.4%
Revenue CAGR
1.8%
Current Ratio
0.84x
Debt / Equity
7.74x
Return on Equity
252.3%
Earnings Summary
The Clorox Company, a long‑standing consumer staples manufacturer, focuses on household and healthcare essentials through brands such as Clorox, Glad, and Brita, operating within the defensive household & personal products sector. Its broad distribution network spans mass merchants, grocery stores, and online channels, sustaining a competitive position in everyday consumer demand. In the most recent quarters, Clorox’s revenue grew from $1.688B in Q2 2026 to $1.948B in Q4 2026, a 15% year‑over‑year increase, while EPS rose from $1.39 in Q2 2026 to $1.66 in Q4 2026, reflecting a 19% EPS gain. The company beat earnings estimates in Q2 2026 (actual $1.39 vs. $1.57 estimate) and Q4 2026 (actual $1.66 vs. $1.65 estimate), but missed the Q1 2025 estimate (actual $1.45 vs. $1.56 estimate). Revenue trends show a steady acceleration, with Q3 2025 revenue at $1.429B and Q4 2025 at $1.686B, indicating consistent top‑line growth. Historically, Clorox has maintained double‑digit revenue growth over the past three years, with EPS growth fluctuating but generally positive; the company has delivered earnings beats in 5 of the last 7 quarters, underscoring a pattern of outperforming consensus despite occasional misses. Recent news highlights a cautious valuation stance from Goldman Sachs and Wells Fargo, who lowered price targets, and a report of demand softness and margin compression that could temper future profitability.

EPS

EstBeatMiss
$0.46$1.14$1.82$2.50$3.18Q2'25Q3'25Q2'26Q3'26Q4'26Q1'27
QtrEstActual+/−
Q1'27$1.09 - -
Q4'26$1.65$1.66+0.9%
Q3'26$1.55$1.64+6.1%
Q2'26$1.57$1.39-11.5%
Q3'25$0.78$0.85+9.2%
Q2'25$2.21$2.87+29.7%

Revenue

EstBeatMiss
$1.3B$1.5B$1.7B$1.9B$2.1BQ2'25Q3'25Q2'26Q3'26Q4'26Q1'27
QtrEstActual+/−
Q1'27$1.9B - -
Q4'26$1.9B$1.9B+1.6%
Q3'26$1.7B$1.7B+0.1%
Q2'26$1.7B$1.7B+0.0%
Q3'25 - $1.4B -
Q2'25 - $2.0B -

Market Data

CLX Stock Snapshot

BEARISH18/100
$83.02−$0.50 (0.6%)
Market cap
9.83B
P/E ratio
16.8
Day range
$82.72 – $84.40
News sentiment
64/100 · Bullish
Analyst target
$100.06 (+20.5%)
Consensus
Hold · 28 analysts
52-week range+4.9% off low · -35.6% from high
$79.12$128.90
Price $83.02 DailyIQ Est. $90.42

Price action on CLX is defensive - rallies are being sold rather than extended. Company-specific news dominates here; sector-level flows matter less than for larger names.

Reverse DCF

What growth is priced into CLX?

CHEAP

At today's price, The Clorox Company needs to grow free cash flow about -6.5% a year for the next 10 years to justify its valuation at a 6.70% cost of capital. Over its actual history it has compounded free cash flow at 2.6% a year, so the market is asking for 9.1 percentage points below its own delivered rate. On that basis CLX looks priced below what its own growth record supports.

Implied FCF growth
-6.5%
Historical FCF CAGR
2.6%
Growth gap
-9.1 pts
Verdict
CHEAP
Discount rate (WACC)
6.70%
Beta
0.49

Behaviour On Record

What CLX's own history says about today's numbers

Realized volatility (21d)
27.7% 80th pct
Below its peak
-65.6%
vs 200-day average
-19.1%
Up days (1y)
44%

The Clorox Company is currently running 27.7% annualised volatility over the last 21 sessions. Measured against CLX's own 13 years of daily returns rather than a market-wide average, that is the 80th percentile — elevated for this stock, against a typical reading of 19.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

CLX is trading -65.6% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -19.9%, and the deepest was -40.1% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -19.1% from its 200-day moving average. Against every other day in its history, that gap ranks at the 2nd percentile — a narrower gap than it typically runs. Over the past year CLX closed higher on 44% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 13 years of records, CLX finished the month higher 4 of 13 times, with a median return of -1.6% and an average of -0.1%. Its strongest month historically has been June at +2.0% on average, its weakest September at -3.4%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: CLX has opened more than 2% away from the prior close in 52 of 3,267 sessions (1.6% of the time), with the largest gaps running +5.9% and -5.0%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, CLX moved an average of 4.4% in the session after earnings, closing higher 2 of those 3 times, with a median move of +5.0% and a largest of +5.8%.

All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against CLX's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of CLX's sector?

The Clorox Company sits in the Consumer Staples sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (improving).

Sector rank
#5 of 12
Sector state
Improving
Sector rotation score
45

Options Market

What is the options market pricing for CLX?

CallsPuts

For The Clorox Company's nearest expiry (2026-10-16, 9 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.78), with at-the-money implied volatility around 37.0%. The options market is pricing roughly a ±5.1% move by that expiry — a range of about $78.84–$87.28.

Put/call ratio (2026-10-16)
0.78
ATM implied volatility
37.0%
Total open interest
24,322
Expected move by 2026-10-16
±5.1% ($78.84–$87.28)

Analyst Rating Changes

Are analysts turning bullish or bearish on CLX?

Citigroup most recently reiterated its rating on The Clorox Company to Neutral on Sep 11, 2026 with a price target of $97 (from $100). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
Citigroup — Neutral
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Sep 11, 2026CitigroupMaintainedNeutral$100 → $97
Sep 11, 2026Wells FargoMaintainedEqual-Weight$102 → $90
Aug 4, 2026UBSMaintainedNeutral$100 → $105
Aug 4, 2026JP MorganMaintainedUnderweight$92 → $95
Aug 4, 2026CitigroupMaintainedNeutral$97 → $100
Aug 4, 2026Wells FargoMaintainedEqual-Weight$95 → $102
Aug 4, 2026Evercore ISI GroupMaintainedUnderperform$98 → $99
Jul 28, 2026JefferiesDowngradeBuy → Hold$125 → $98
Jul 23, 2026Evercore ISI GroupMaintainedUnderperform$110 → $98
Jul 21, 2026BarclaysMaintainedUnderweight$85 → $86
Jul 20, 2026BNP ParibasMaintainedNeutral$97 → $95
Jul 16, 2026JP MorganMaintainedUnderweight$95 → $92

CLX Competitive Positioning

The Clorox Company (CLX) is tracked alongside these names in Household & Personal Products on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

64/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
The article evaluates Clorox (CLX) as a dividend stock with a 6%+ yield following recent selloffs. It highlights that long‑term yields have risen above 5%, creating a favorable environment for dividend‑seeking investors. The analysis notes potential valuation upside for CLX while acknowledging inflationary headwinds and payout risks. Overall, the piece presents CLX as a compelling buy for income investors amid market turbulence.
What did this article say?
Clorox Company launched the Clorox Purell ProCare™ health platform, merging its CloroxPro division with the recently acquired GOJO brand. The integration provides professional and healthcare customers unified access to Clorox, Purell, Pine‑Sol, and Glad through a single sales and distribution network. This move is intended to broaden Clorox’s health and hygiene ecosystem and strengthen its position with institutional clients.
What did this article say?
The article compared Colgate-Palmolive and The Clorox Company, noting that CLX is actively rebuilding market share and strengthening its brands. It highlighted CLX’s efforts to improve productivity and expand its health and hygiene platform through the GOJO acquisition. The piece emphasized that CLX is leveraging innovation, pricing, and digital capabilities to navigate a volatile consumer staples environment. These strategic moves suggest a modest positive outlook for CLX’s long‑term growth potential.
What did this article say?
Goldman Sachs reduced its price target for Clorox (CLX) to $74 from $77 while keeping a sell recommendation. The downgrade reflects a more cautious view of the company’s near‑term prospects. The move signals a modest negative outlook for CLX’s valuation.
What did this article say?
Wells Fargo lowered its price target for Clorox (CLX) to $85 from $90 while retaining an equal‑weight rating. The adjustment indicates a more conservative assessment of the company’s valuation. The change suggests a modest negative stance on CLX’s future earnings potential.
What did this article say?
Wells Fargo analyst Chris Carey reduced Clorox’s price target from $90 to $85 while keeping the stock on an equal‑weight recommendation. The downgrade reflects concerns over the company’s earnings outlook and competitive pressures in the consumer‑goods sector. The move signals a modest negative view for Clorox’s near‑term valuation, potentially impacting investor sentiment.
What did this article say?
Clorox (CLX) reported a significant decline in its stock price, falling roughly 35% over the past year, with half of that drop occurring in the last month. The company announced a full‑year outlook cut, citing inflationary pressures, supply chain disruptions, and early costs associated with its hand sanitizer acquisition. These factors have weakened investor confidence and highlighted the firm’s vulnerability in a higher‑interest‑rate environment. The downgrade reflects a confirmed negative impact on CLX’s financial prospects.
What did this article say?
Clorox’s portfolio of household brands, including Clorox bleach, Glad, and Brita, accounts for more than 80% of sales and positions the company as a market leader in many categories. The company’s strong brand moat has historically shielded it from competitive pressure, yet recent earnings revealed that demand softness, rising input costs, and margin compression are eroding profitability. Management acknowledged that while brand loyalty remains high, the company must navigate tighter cost structures and a more price‑sensitive consumer base. The analysis suggests that Clorox’s competitive edge is intact, but the financial impact of these headwinds could temper future growth expectations.
What did this article say?
Clorox reported Q2 earnings that surpassed analyst consensus, contributing to a group revenue beat of 2.1%. The company’s guidance for the next quarter was 1.6% above expectations, indicating confidence in future performance. However, despite the earnings beat, Clorox’s share price fell as part of a broader 9.5% decline in household product stocks following the earnings season. The decline reflects market caution over the sector’s ability to sustain growth amid shifting consumer preferences toward eco‑friendly products.
What did this article say?
Clorox completed the acquisition of GOJO Industries, expanding its health and hygiene portfolio. The company finished a five‑year digital transformation program, rolling out a new U.S. ERP system. Improved demand planning, lower inventory, and automation are expected to deliver productivity benefits beginning in fiscal 2027 and extending into fiscal 2028. These initiatives aim to strengthen market share and support sustainable growth in a challenging consumer environment.

Technical Analysis

Real-time indicators across multiple timeframes

18
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
3 tracked managers · $324.37M combined position · 2 adding, 1 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Geode Capital Management, LLC▲ Buy3,265,5512.75%$310.44M2026-08-12
Marshall Wace, LLP▼ Sell123,7540.10%$11.81M2026-08-13
Neuberger Berman Group LLC▲ Buy22,2890.02%$2.13M2026-08-13
Q2 2026 flow:37.8K sh bought ($3.60M)223.7K sh sold ($21.35M)net -185.8K sh (−$17.75M)
Congressional Trading Activity
23 disclosed trades · ~$658.5K est. traded value · 10 buys, 13 sells
MemberChamberStateTypeAmountTradedFiled
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-12-192026-01-12
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-242025-08-13
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-04-112025-05-08
Tommy TubervilleSenateAL▲ Buy$1K - $15K2024-04-292024-05-15
Tommy TubervilleSenateAL▼ Sell$50K - $100K2023-10-312023-11-16
Tommy TubervilleSenateAL▲ Buy$100K - $250K2023-10-252023-11-16
Tommy TubervilleSenateAL▲ Buy$100K - $250K2023-09-202023-10-13
Shelley Moore CapitoSenateWV▼ Sell$1K - $15K2023-06-142023-07-17
Tommy TubervilleSenateAL▼ Sell$1K - $15K2023-05-172023-06-15
Tommy TubervilleSenateAL▼ Sell$1K - $15K2023-05-082023-06-15
Tommy TubervilleSenateAL▼ Sell$1K - $15K2022-12-092023-01-13
Tommy TubervilleSenateAL▼ Sell$1K - $15K2021-09-292021-10-15
Tommy TubervilleSenateAL▲ Buy$1K - $15K2021-03-292021-07-23
Shelley Moore CapitoSenateWV▼ Sell$1K - $15K2020-12-312021-01-12
Ron WydenSenateOR▼ Sell$1K - $15K2020-08-242020-09-24
Ron WydenSenateOR▲ Buy$1K - $15K2020-08-052020-08-29
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2018-04-242019-05-09
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2018-04-052019-05-09
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2016-04-192016-05-04
Sheldon WhitehouseSenateRI▼ Sell$1K - $15K2014-03-132014-03-26
Sheldon WhitehouseSenateRI▼ Sell$15K - $50K2014-02-192015-09-03
Sheldon WhitehouseSenateRI▼ Sell$15K - $50K2014-01-312014-02-27